Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 
The good —  Vertex submits NDA for CF drug 
The bad — MacroGenics reports patient deaths in prostate cancer ADC trial  
The ugly — FTC extends review of Novo-Catalent deal

FDA approves Amgen's T-cell engager for lung cancer, BioMarin announces layoffs, FDA delays Ascendis drug review [The good, the bad, the ugly]

The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more

Podbean

Off Script: A Pharma Manufacturing Podcast

Neurocrine wins FDA nod for 'sprinkle' Ingrezza, Moderna-Metagenomi deal ends, Emergent's layoffs [The good, the bad, the ugly]

Vertex submits NDA for CF drug, MacroGenics reports ADC prostate cancer trial patient deaths, FTC extends review of Novo-Catalent deal [The good, the bad, the ugly]